Delayed response and survival from NovoTTF-100A in recurrent GBM
JL Villano, LE Williams, KS Watson, N Ignatius… - Medical Oncology, 2013 - Springer
JL Villano, LE Williams, KS Watson, N Ignatius, MT Wilson, T Valyi-Nagy, EA Michals…
Medical Oncology, 2013•SpringerWe present a 48-year-old male with recurrent glioblastoma (GBM) who was enrolled in the
NovoTTF-100A landmark phase III study and has been on device for> 6 years. During this
time, his magnetic resonance images demonstrated initial growth followed by a slow
decrease in enhancement with continued residual disease. Long-term survivors in patients
with recurrent GBM are rare, especially in the absence of definitive local treatment such as
surgery or radiosurgery. We present the clinical, imaging and pathological findings for this …
NovoTTF-100A landmark phase III study and has been on device for> 6 years. During this
time, his magnetic resonance images demonstrated initial growth followed by a slow
decrease in enhancement with continued residual disease. Long-term survivors in patients
with recurrent GBM are rare, especially in the absence of definitive local treatment such as
surgery or radiosurgery. We present the clinical, imaging and pathological findings for this …
Abstract
We present a 48-year-old male with recurrent glioblastoma (GBM) who was enrolled in the NovoTTF-100A landmark phase III study and has been on device for >6 years. During this time, his magnetic resonance images demonstrated initial growth followed by a slow decrease in enhancement with continued residual disease. Long-term survivors in patients with recurrent GBM are rare, especially in the absence of definitive local treatment such as surgery or radiosurgery. We present the clinical, imaging and pathological findings for this patient in relation to use of the NovoTTF-100A device.
Springer